Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Hypertension. 2019 Oct 21;74(6):1409–1419. doi: 10.1161/HYPERTENSIONAHA.119.13676

Figure 3. Inhibition of ET-1 receptors did not improve EDR or enhance eNOS activity in obese and hyperlipidemic mice.

Figure 3.

A) Graphical depiction of experimental design. Western diet-fed mice were administered either the dual ET-1 receptor antagonist, Bosentan (Bos; 100mg/kg; chronic ET-1 receptor blockade) or vehicle control (Con; reduced fat peanut butter) daily for eight weeks. B) Mean arterial pressure (MAP) determined via tail-cuff monitoring; n=9/group. C) Endothelium-dependent (ACh, ACH/SNP) and –independent (SNP) vasomotor function responses in the aorta; n=9/group. D) Western blot determination of aortic eNOS activation (p-eNOS Ser1177/total eNOS) in aortic homogenates; n=9/group. Representative Western blot images are depicted. All data are expressed as means ± SEM. *p<0.05 vs Con. AUC, area under the curve.